a Parkinson's disease feed — research, treatments, lived experience, in plain language
Vyalev, Abbvie‘s continuous under-the-skin infusion formulation of levodopa/carbidopa, reduces off time and eases motor and some nonmotor symptoms in adults with advanced Parkinson’s disease. That’s…
Pump therapies (LCIG, apomorphine) On/off fluctuations Dyskinesia Gait & freezing Pain Insomnia Levodopa formulations Trial readouts
Vyalev (also sold as Produodopa in Europe) is a therapy made by AbbVie that delivers levodopa and carbidopa — the standard Parkinson's medications — continuously under the skin via a small pump, 24 hours a day. Unlike oral pills, which cause levodopa levels in the blood to rise and fall with each dose, the pump keeps levels steadier. This matters because those peaks and troughs are what drive two of the most disabling problems in advanced Parkinson's: off episodes (periods when medication stops working and symptoms return, sometimes suddenly) and dyskinesia (involuntary, uncontrolled movements caused by too much levodopa at once).
The article reports six-month interim results from ROSSINI (NCT06107426), an ongoing real-world observational study following 427 adults with advanced Parkinson's across 10 countries in routine clinical care — not a tightly controlled lab trial, but an important first look at how the therapy performs in everyday practice. Among the 105 newly treated participants with evaluable data, daily off time dropped by an average of 2.8 hours (about 53%), and daily dyskinesia time fell by 1.8 hours (also roughly 53%). Standard motor scores improved significantly, freezing of gait lessened, and nonmotor symptoms — pain, sleep disturbances, and gut problems — also got better. Quality of life scores improved, especially in mobility, emotional well-being, and physical comfort. About a third of participants stopped treatment within six months, most commonly due to personal choice or side effects; hallucinations and skin infections at the infusion site each affected around 6% of patients.
For someone living with advanced Parkinson's who still experiences hours of daily off time despite optimised oral medication, this real-world data adds meaningful reassurance that Vyalev performs outside of clinical trials similarly to how it did inside them. It is already approved in the US and Europe, so this is a conversation you can have with your neurologist now — not a future hope. The key question to raise is whether your off-time burden justifies moving to a pump, and whether the practical demands (wearing a device 24/7, managing infusion-site care) are right for your situation. A 12-month interim analysis of 200 patients is planned next, which will give a clearer picture of longer-term tolerability.
Pump therapies (LCIG, apomorphine) On/off fluctuations Dyskinesia Gait & freezing Pain Insomnia Levodopa formulations Trial readouts
Vyalev (also sold as Produodopa in Europe) is a therapy made by AbbVie that delivers levodopa and carbidopa — the standard Parkinson's medications — continuously under the skin via a small pump, 24 hours a day. Unlike oral pills, which cause levodopa levels in the blood to rise and fall with each dose, the pump keeps levels steadier. This matters because those peaks and troughs are what drive two of the most disabling problems in advanced Parkinson's: off episodes (periods when medication stops working and symptoms return, sometimes suddenly) and dyskinesia (involuntary, uncontrolled movements caused by too much levodopa at once).
The article reports six-month interim results from ROSSINI (NCT06107426), an ongoing real-world observational study following 427 adults with advanced Parkinson's across 10 countries in routine clinical care — not a tightly controlled lab trial, but an important first look at how the therapy performs in everyday practice. Among the 105 newly treated participants with evaluable data, daily off time dropped by an average of 2.8 hours (about 53%), and daily dyskinesia time fell by 1.8 hours (also roughly 53%). Standard motor scores improved significantly, freezing of gait lessened, and nonmotor symptoms — pain, sleep disturbances, and gut problems — also got better. Quality of life scores improved, especially in mobility, emotional well-being, and physical comfort. About a third of participants stopped treatment within six months, most commonly due to personal choice or side effects; hallucinations and skin infections at the infusion site each affected around 6% of patients.
For someone living with advanced Parkinson's who still experiences hours of daily off time despite optimised oral medication, this real-world data adds meaningful reassurance that Vyalev performs outside of clinical trials similarly to how it did inside them. It is already approved in the US and Europe, so this is a conversation you can have with your neurologist now — not a future hope. The key question to raise is whether your off-time burden justifies moving to a pump, and whether the practical demands (wearing a device 24/7, managing infusion-site care) are right for your situation. A 12-month interim analysis of 200 patients is planned next, which will give a clearer picture of longer-term tolerability.